Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial i
Go back to Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial i| Regeneron (NASDAQ: REGN) | Delayed: 798.17 +13.32 (1.70%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $784.85 | 52 Week High | $592.36 | |||
| Open | $786.03 | 52 Week Low | $325.35 | |||
| Day High | $801.44 | P/E | 209.49 | |||
| Day Low | $779.96 | EPS | $3.81 | |||
| Volume | 704,524 | |||||
